Events & presentations
Past events
-
Zealand Pharma conference call on collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide
-
Zealand Pharma Annual Report 2024
-
Jefferies London Healthcare Conference 2024
-
Zealand Pharma Interim Report Q3 2024
-
Zealand Pharma Interim Report H1 2024
-
Zealand Pharma topline results for Phase 1b trial of petrelintide
-
Zealand Pharma Interim Report Q1 2024
-
Zealand Pharma Annual Report 2023
-
Zealand Pharma’s Obesity R&D Event
-
Zealand Pharma Interim Report Q3 2023
-
Zealand Pharma Interim Report H1 2023
-
Zealand Pharma Interim Report Q1 2023
-
Zealand Pharma Annual Report 2022
-
Zealand Pharma Interim Report Q3 2022
-
Zealand Pharma Interim Report H1 2022
-
Zealand Pharma Interim Report Q1 2022
-
Zealand Pharma Corporate Update Conference Call
-
Zealand Pharma Annual Report 2021
An overview of Zealand Pharma
CORPORATE PRESENTATION
This presentation is intended for shareholders and investors.
Any information concerning pharmaceuticals (including compounds under development) contained within these materials is not intended as advertising or medical advice.
Obesity R&D event
Featured Event
We hosted an event for investors to discuss the scientific rationale and clinical potential of our differentiated product candidates targeting obesity. Speakers at the event were Adam Steensberg, our CEO; and David Kendall, our CMO and Head of R&D, joined by three leading external experts.
